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High density lipoproteins (HDL), through activity of the main protein component apolipoprotein A-I
(ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess cholesterol from
atherosclerotic plaque. In this study, we demonstrate that the bromodomain and extraterminal domain
(BET) inhibitor RVX-208 increases ApoA-I gene transcription and protein production in human and
primate primary hepatocytes. Accordingly, RVX-208 also signiﬁcantly increases levels of ApoA-I, HDL-
associated cholesterol, and HDL particle number in patients who received the compound in recently
completed phase 2b trials SUSTAIN and ASSURE. Moreover, a post-hoc analysis showed lower instances
of major adverse cardiac events in patients receiving RVX-208. To understand the effects of RVX-208 on
biological processes underlying cardiovascular risk, we performed microarray analyses of human primary
hepatocytes and whole blood treated ex vivo. Overall, data showed that RVX-208 raises ApoA-I/HDL and
represses pro-inﬂammatory, pro-atherosclerotic and pro-thrombotic pathways that can contribute to
CVD risk.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease (CVD) is the leading cause of death
within industrialized nations and accounts for approximately one
out of three deaths in the United States [1]. Epidemiological studies
show an inverse correlation between high density lipoprotein
associated cholesterol (HDL-c) and incidence of CVD [2,3], sug-
gesting a cardioprotective role for HDL. HDL is a heterogeneous
collection of lipoprotein particles with roles in inﬂammation,
oxidation and reverse cholesterol transport (RCT). The most com-
mon underlying cause of CVD is atherosclerosis, which leads to
development of cholesterol-rich plaques in the arterywall that may
rupture to induce acute events [6]. HDL mediates cholesterol efﬂux
from atherosclerotic plaque via RCT, potentially slowing down the
atherogenesis process and stabilizing the plaque. The concept that00, 4820 Richard Road SW,
ong).
Ireland Ltd. This is an open accessincreased production of HDL can decrease atherosclerosis is sup-
ported by studies inwhich ApoA-I, the major protein component of
HDL, was infused into subjects, resulting in regression of coronary
plaque [7,8]. Currently, strategies that increase HDL-c are being
evaluated in the clinic with the objective to reduce cardiovascular
events [9,10]. However, ﬁndings frommost of these studies suggest
that raising concentrations of HDL-c is not sufﬁcient to reduce CVD
risk [11]. Conversely, increasing HDL functionality to augment RCT
may potentially decrease cardiovascular events [11,12].
RVX-208 is an orally active small molecule being developed for
the treatment of CVD [13,14]. Recent evidence indicates that serum
cholesterol efﬂux capacity, which represents a critical step in RCT,
provides a more accurate prediction of cardiovascular events than
levels of HDL-c [11,12]. In preclinical studies of African green
monkeys, RVX-208 increased plasma ApoA-I, HDL-c (pre-beta and
alpha HDL), and enhanced the ability of serum to efﬂux cholesterol
via the ABCA1, ABCG1, and SR-BI-dependent pathways [15]. The
phase 1a trial showed that serum from healthy volunteers taking
RVX-208 had increased cholesterol efﬂux capacity [15], consistentarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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phase 2a ASSERT trial of statin-treated patients with stable coro-
nary artery disease, those receiving RVX-208 for 12 weeks had
signiﬁcant increases in HDL-c and large HDL, indicating elevated
production of ApoA-I and efﬂux of cholesterol to nascent HDL
particles [14]. The same trial showed that ApoA-I and HDL-c levels
increased rapidly from week 8 to week 12, suggesting peak phar-
macological effect had not been reached. Subsequently, SUSTAIN
and ASSURE, 24 and 26 week phase 2b trials were undertaken to
assess the long term efﬁcacy of RVX-208 [13].
RVX-208 increases ApoA-I transcription through an epigenetic
mechanism that is mediated by bromodomain and extra-terminal
domain (BET) protein 4 (BRD4) [16,17]. BRD4 can recruit and
tether the positive transcription elongation factor (P-TEFb) to gene
promoters, thereby promoting transcription [18]. BET proteins
contain two bromodomains that interact with acetylated lysines on
histone tails [19]. RVX-208 disrupts this interaction by selectively
binding to the second bromodomain (BD2). This leads to differen-
tial effects on gene expression as compared to pan BET inhibitors
(BETi) [17]. RVX-208 is currently the only BD2 selective BETi in
clinical development for CVD.
In vitro, increased ApoA-I transcription is a recognized property
of BETi in hepatocarcinoma cells [15,16,20e22]. In this study, hu-
man and primate primary hepatocyte systems that maintain many
characteristics of the liver were used to conﬁrm induction of ApoA-I
gene expression and protein production in response to BETi,
including RVX-208. Further, we explored the effects of RVX-208 on
known markers of CVD risk in the SUSTAIN and ASSURE trials and
in cultured primary hepatocytes and whole blood using micro-
arrays. Results indicate that, in addition to expected effects on li-
poprotein proﬁle, RVX-208 represses pro-inﬂammatory, pro-
atherosclerotic and pro-thrombotic pathways that can contribute
to CVD risk.2. Methods
2.1. SUSTAIN and ASSURE human trials
Clinical data from two randomized, double-blind, placebo-
controlled, similarly designed phase 2b clinical trials of RVX-208
treatment over 6 months in patients with coronary artery disease
(CAD) were retrospectively analyzed to evaluate the effects of RVX-
208 on various lipid, inﬂammatory and metabolic biomarkers as
well as incidence of major adverse cardiac events (MACE) deﬁned
as death, nonfatal myocardial infarction, coronary revascularization
and hospitalization for unstable angina or heart failure. The full
design and rationale of the two studies, SUSTAIN (NCT01423188)
and ASSURE (NCT01067820) has been published previously [13].
The similarities of the clinical trial designs include the inclusion
criteria, identical dosing regimen of RVX-208, comparable treat-
ment durations and the replicate placebo groups, providing ratio-
nale for the data to be pooled and analyzed. The major difference in
the patient groups was the severity of the CAD. In the SUSTAIN
study, patients were required to have documented stable coronary
artery disease whereas in the ASSURE study patients were sched-
uled to undergo coronary angiography for a clinical indication. This
difference provided a broader and more integrated analysis of the
effects of RVX-208 across the CAD spectrum over 6 months of
treatment. A total of 55 matching biomarkers were collected at
various time points throughout the course of both studies in
addition to several screening parameters. Secondary outcome
measures included HDL-c, ApoA-I and HDL-subclasses. The
proApoA-I clinical data were collected in the SUSTAIN study.2.2. Statistical analysis
The change from baseline to 24/26 weeks (SUSTAIN/ASSURE) in
the efﬁcacy parameters was analyzed using a 2-sided Van Elteren
test of RVX-208 vs placebo, stratiﬁed by study in the modiﬁed-
intent-to-treat patient population. For each analysis, the median
change from baseline, median percentage change from baseline,
median difference between treatment groups and p-value for the
difference between RVX-208 and placebo are presented. Shapir-
oeWilk tests on each parameter illustrated non-normal distribu-
tion (p < 0.001) and thus non-parametric statistical tests were used.
Baseline was deﬁned as the last non-missing value prior to
randomization. The censoring date for the quantiﬁcation of MACE
was taken to be 30 days after the last dose, and only the ﬁrst event
was used.2.3. Chemical synthesis
RVX-208 (2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-
dimethoxyquinazolin-4(3H)-one) and JQ1 were synthesized as
described previously by NAEJA Pharmaceuticals (Edmonton, Can-
ada) or IRIX Pharmaceuticals (Florence, SC) [23e25]. GSK1210151A
(IBET-151) was purchased from ShangHai Biochempartner Co. Ltd.
(Wuhan, China) while GSK525762 (IBET-762) was from Chemscene
(Monmouth Junction, NJ).2.4. Primary hepatocyte culture systems
Human hepatocytes in the HepatoPac® microliver system pre-
pared by Hepregen (Medford, MA) and cryopreserved human he-
patocytes (CellzDirect/Life Technologies) were plated as
recommended by the suppliers. RVX-208 treatments were per-
formed in media recommended by the supplier containing 0.1 or
0.2% DMSO.2.5. mRNA abundance
mRNA analysis was performed by TaqMan® assay based real-
time PCR as described previously [16].2.6. ELISA
A rabbit monoclonal anti-proApoA-I antibody was generated
using a synthetic peptide RHFWQQ_DEPP. The antibody was used
to coat EIA/RIA high binding surface microplates (Corning) over-
night. Plates were washed, and then blocked with 5% skim milk.
Recombinant poly-histidine tagged human proApoA-I (Genscript,
Piscataway, NJ) was used as a standard. Recombinant protein or
samples were introduced onto plates, incubated with anti-human
ApoA-I (Calbiochem # 178470), and then with HRP conjugated
anti-mouse IgG (Calbiochem # 401253). Color was developed by
treatment with tetramethylbenzidine, followed by sulfuric acid.
Plates were read on a Thermo Scientiﬁc Multiskan GO Spectro-
photometer at 450 nm. ApoA-I ELISA was performed in a similar
fashion as proApoA-I, except using the mouse anti-human ApoA-I
antibody (Calbiochem # 178470). The standard was puriﬁed ApoA-I
(Calbiochem # 178452) and it was detected using a polyclonal
rabbit anti-human ApoA-I antibody (Calbiochem # 178422), fol-
lowed by HRP conjugated anti-rabbit IgG (Calbiochem # 401353).
Media was collected from Huh-7 cells after 48 h, then incubated
with recombinant bone morphogenetic protein-1 (R&D Systems)
followed by ELISA to measure remaining proApoA-I.
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Proteins in media from hepatocyte cultures maintained for 72 h
were separated in 4e12% NuPAGE Bis-Tris gels (Invitrogen/Life
Technologies) under reducing conditions. Proteins were transferred
to a nitrocellulose membrane (Bio-Rad). Immunoblots were per-
formed with rabbit anti-proApoA-I followed by peroxidase conju-
gated anti-rabbit IgG (Calbiochem # 401353). Immunoreactive
proteins were visualized by chemiluminscence (Pierce Biotech-
nology). The primary antibody used to detect total ApoA-I was from
Calbiochem (# 178422).
2.8. Microarrays
Primary human hepatocytes (CellzDirect/Life Technologies)
were plated in 24 well format at 500,000 cells/well, then overlaid
with Matrigel™ as recommended by the supplier. Cells were
treated with RVX-208 at 30mM for 48 h. Total RNA was extracted
with the mirVana™ kit (Ambion) and sent to Asuragen Inc. (Austin,
TX) for microarray analysis using Affymetrix Human Genome U133
Plus 2.0 Array. After obtaining informed consent, whole blood was
collected from three healthy volunteers into BD Vacutainer Sodium
Heparin tubes (# 367874) and samples were inverted 10 times.
Blood samples (1mL) were combinedwith 1mL of RPMI containing
2 mM glutamine, 1% penicillin/streptomycin, 20% FBS and 20mM
RVX-208 or vehicle (0.1% DMSO), followed by a 3 h or 24 h incu-
bation at 37 C in an tissue culture incubator (CO2 concentration
5.5%). Treated samples were transferred to a PAXgene RNA tube
(PreAnalytix/Qiagen), inverted 5 times and frozen. RNA was iso-
lated with the PAXgene RNA kit according to manufacturer's in-
structions. Microarrays were performed by Asuragen using the
Affymetrix human U133 plus 2.4 Array. Data were analyzed using
Ingenuity Pathway Analysis Software (Qiagen).
2.9. Multi-analyte proﬁling (MAP)
Plasma samples were collected from 20 RVX-208 treated sub-
jects and 10 placebo treated subjects at baseline and after ﬁnal dose
in the ASSURE trial. Levels of plasma proteins were quantitated
using microsphere-based immuno-multiplexing analysis. Changes
in amounts of each protein were calculated versus baseline. Sha-
piroeWilk tests were used to determine data distribution. For
normally distributed parameters, paired student t-tests were used
to calculate statistical signiﬁcance, while for non-normally
distributed parameters, Wilcoxon signed-rank tests were applied.
3. Results
3.1. RVX-208 increases ApoA-I mRNA in primary human hepatocyte
systems
RVX-208 and other BET inhibitors enhance ApoA-I gene activity
in hepatocarcinoma cell lines [15,16,20e22]. Primary hepatocytes
mimic in vivo activity more accurately than cell lines, and so the
effects of RVX-208 on ApoA-I expression were examined in two
different primary liver systems including HepatoPac® microliver
cultures (Hepregen Corp., Medford, MA) and cryopreserved human
hepatocytes (Cellz Direct, Life Technologies). The HepatoPac®
microliver system co-cultures stromal cells with human hepato-
cytes to provide an environment that enhances hepatocyte function
in vitro [26,27]. In such co-cultures, hepatocytes retain liver-
speciﬁc characteristics including albumin secretion, synthesis of
urea and formation of bile canaliculi [28]. The cryopreserved sys-
tem utilizes human hepatocytes plated on collagen to form
monolayers. In bothmodels, exposure to RVX-208 increased ApoA-ImRNA in a time and dose dependentmanner (Fig.1A and B). Similar
observations (data not shown) were made using RegeneMed 3-D
liver cell cultures (RegeneMed Inc., San Diego, CA). Together the
results show that RVX-208 induces ApoA-I expression in a variety
of human hepatocyte systems. A similar ﬁnding was evident in 3-D
cultures of primary hepatocytes from African green monkeys.
Increased levels of ApoA-I mRNA were also measured in Hep-
atoPac®microliver and cryopreserved hepatocytes treatedwith the
pan BET inhibitors JQ1, I-BET762 and I-BET151 (Fig. 1C). The
chemical scaffold for these compounds is distinct from RVX-208,
indicating enhanced ApoA-I transcription is a property of these
BET inhibitors. I-BET762 is being tested in humans for treating NUT
midline carcinoma and other cancers (ClinicalTrials.gov
NCT01587703), while the related compound I-BET151 induces
ApoA-I transcription in vitro [21].
Next, actinomycin D, an inhibitor of transcription, was used to
block induction of ApoA-I mRNA by RVX-208 in cryopreserved
primary human hepatocytes (Fig. 1D), supporting the transcrip-
tional mechanism demonstrated in carcinoma cells [16]. Cyclo-
heximide, an inhibitor of protein synthesis, also abrogated ApoA-I
mRNA induction (Fig. 1D). These ﬁndings suggest that RVX-208
stimulates ApoA-I gene transcription, and although this process is
BET protein-dependent, it involves synthesis of a protein inter-
mediate in human liver cells.
3.2. RVX-208 increases proApoA-I protein secretion
To determine if RVX-208 induced transcription of the ApoA-I
gene leads to synthesis of the protein in vitro and in vivo, an
antibody targeting proApoA-I was developed. ApoA-I is secreted
from the liver and intestine as proApoA-I which carries an N-ter-
minal hexapeptide [29,30] that is cleaved by bone morphogenetic
protein-1 (BMP-1) [31,32]. Thus, levels of circulating proApoA-I
reﬂect recently synthesized and secreted protein that has not yet
been processed. An antibody directed against the cleavage motif
plus 4 amino acids (RHFWQQ_DEPP) was created, and it recognized
a single band in immunoblots from primary human hepatocytes,
illustrating speciﬁcity (Fig. 2A). A modest increase in both
proApoA-I and total ApoA-I was detected byWestern blots in spent
media from primary hepatocytes exposed to RVX-208. The abun-
dance of mature and proApoA-I in spent media was dose-
dependent (Fig. 2B). The ELISA signal was eliminated by digestion
with recombinant BMP-1, consistent with recognition of proApoA-I
by the antibody (Fig. 2C). JQ1 also induced proApoA-I mRNA and
protein levels, conﬁrming that BET inhibition increases ApoA-I
production as expected [33]. In the SUSTAIN trial, statistically sig-
niﬁcant increases in both serum proApoA-I (þ2.37%; p < 0.05) and
total ApoA-I (þ4.38%; p < 0.01) proteins were observed following
treatment with RVX-208 versus placebo. Importantly, these protein
changes were accompanied by an increase in HDL-c (p < 0.001) and
HDL particle number (p < 0.05), suggesting that, in humans, RVX-
208 increases production of ApoA-I protein that matures to HDL.
3.3. RVX-208 impacts CVD risk in the SUSTAIN and ASSURE trials
Phase 2b SUSTAIN and ASSURE trials were designed to evaluate
the effects of RVX-208 on CVD [34,35]. Both trials enrolled patients
with established CVD receiving standard of care therapy, including
statins and then randomized to receive either RVX-208 or placebo
for a period of 6 months. After combining data from the two trials,
therewas a total of 499 subjects that received either 100mg b.i.d. of
RVX-208 (n ¼ 331) or placebo (n ¼ 168) (Fig. 3). Pooled data
showed that RVX-208 treatment led to a statistically signiﬁcant
increase in HDL-c, ApoA-I, large HDL particles and average HDL
particle size of 7.69% (p < 0.001), 10.3% (p < 0.01), 30.7% (p < 0.01)
Fig. 1. RVX-208 increases ApoA-I expression in primary hepatocytes in a time and dose dependent manner. Primary human hepatocytes were cultured in the two systems indicated.
(A) Hepatocytes were treated with increasing concentrations of RVX-208 for 48 h, then ApoA-I mRNA abundance determined by TaqMan® real-time PCR. (B) The time course for
ApoA-I induction was performed using RVX-208 at 30mM (HepatoPac® microliver or cryopreserved hepatocytes). (C) Hepatocytes in the indicated culture systems were treated for
48 h with BETi with chemical scaffolds different from RVX-208, then ApoA-I mRNA levels were determined. In the HepatoPac®microliver system, RVX-208 was used at 30mM, JQ1 at
1mM, and I-BET762 at 1mM. In cryopreserved hepatocytes, RVX-208 was used at 30mM, JQ1 at 0.5mM and I-BET151 at 0.9mM. For all data in Fig. 1A through C, p < 0.05 versus DMSO
treated samples at the same time point using two-tailed student's t-tests. D) ApoA-I mRNA induction by RVX-208 is dependent on transcription and production of new protein.
Cryopreserved primary human hepatocytes were treated with the indicated compounds for 48 h. ApoA-I mRNA induction by 30mM RVX-208 is inhibited by 1mM actinomycin D (Act
D) and by 1mM cycloheximide (Cyclohex). All data are the mean from independent triplicate samples, while error bars represent standard deviation. *p < 0.05 N S. ¼ not signiﬁcant.
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tional CVD risk factors and metabolic parameters (blood pressure,
high-sensitivity C-reactive protein [hsCRP] and glucose) were
analyzed, but there were no differences between treatment groups.
Quantiﬁcation of MACE showed 17/168 (10.1%) and 18/331 (5.4%) in
the placebo and RVX-208 treatment groups, respectively (Table 2).
The post-hoc analysis of pooled data from our phase 2b trials shows
that RVX-208 improves the HDL proﬁle and appears to lower MACE
in CVD patients.3.4. RVX-208 regulates pathways that underlie CVD
The observed reduction in MACE (Table 2) was more pro-
nounced than that predicted from changes in ApoA-I/HDL alone.
This implies RVX-208 had other effects that could impact CVD risk.
To explore this, a microarray analysis of cryopreserved hepatocytes
treated with RVX-208 (30mM) was performed. Pathway analysis of
these data showed that RVX-208 downregulates the complement
cascade, ﬁbrin clotting, acute phase response, cholesterol synthesis,
fatty acid synthesis, and diabetes pathways (Table 3). These path-
ways, which are predominantly expressed in the liver, are linked to
processes that are known to affect CVD risk, including atheroscle-
rosis, thrombosis and inﬂammation. Gene sets contributing to
these pathways and the effect of RVX-208 on expression are shown
in Fig. 4.
In addition to the pathways above, it is known that vascular
inﬂammation and atherosclerotic plaque development contribute
to CVD. These processes can be mediated by circulating cells in
blood, such as monocytes, lymphocytes and neutrophils. To assess
the effects of RVX-208 on these cell types, humanwhole blood from
healthy donors was treated ex vivo for 3 or 24 h with 20mM RVX-
208. This dose maximally suppresses inﬂammation markers inboth U937 and peripheral blood mononuclear cells (data not
shown). The gene expression proﬁle in whole blood was examined
bymicroarrays. Mining of the scientiﬁc literature shows that almost
600 genes expressed in multiple cell types have documented roles
in inﬂammation, atherogenesis and angiogenesis [36 and
references therein]. This list of genes was cross-referenced with
our microarray data showing that, in humanwhole blood, RVX-208
affected expression of 64 genes with functional relevance in
atherosclerosis (Fig. 5). Speciﬁcally, RVX-208 downregulated the
expression of chemokines, cytokines, integrins and their cognate
receptors, which control immune cell migration and activation in
atherosclerotic plaque. These genes are implicated in atheroscle-
rotic plaque development and instability. Overall, out of 46 affected
pro-atherogenic genes, 37 were downregulated in response to RVX-
208, whereas 8 out of 18 anti-atherogenic genes were upregulated
by RVX-208 (Fig. 5). Lastly, the top canonical pathways down-
regulated by RVX-208 treatment are involved in cytokine signaling,
cellecell adhesion, extracellular matrix organization, G protein
signaling and Th1/Th2 responses (Table 4). Downregulation of
these pathways may translate into anti-atherogenic effects in hu-
man vasculature.
To conﬁrm the microarray ﬁndings, select proteins were
measured versus baseline in plasma samples collected in the
ASSURE trial using multi-analyte proﬁling to determine effects of
RVX-208 on inﬂammatory cytokines, adhesion molecules and
markers of APR (Table 5). In patients receiving RVX-208, protein
levels of pulmonary and activation-regulated cytokine (CCL18), IL-
18, interleukin-12 subunit p40 and the adhesion molecule ICAM-
1 were signiﬁcantly reduced by 22%, 10%, 6% and 7%, respectively.
Moreover, APR proteins serum amyloid P-component, cerulo-
plasmin and complement C3 were reduced by 7e15% (Table 5).
These data show an effect of RVX-208 on inﬂammatory mediators
Fig. 2. RVX-208 increases secretion of proApoA-I and total ApoA-I protein from cryopreserved human primary hepatocytes. A) Cryopreserved human hepatocytes plated in
duplicate wells were treated with 30mM RVX-208 or DMSO for 72 h. Immunoblots were used to probe for proApoA-I and total ApoA-I in the media. B) Cryopreserved human
hepatocytes were treated for 72 h with RVX-208 or DMSO. ApoA-I and proApoA-I protein in the media were quantiﬁed using ELISA assays. *p < 0.05, **p < 0.01, ***p < 0.001 versus
DMSO treated cells. C) Media from Huh-7 cells was collected and incubated with recombinant human BMP-1. ProApoA-I remaining in the media was determined by ELISA. Data are
the mean from independent triplicate samples, while error bars represent standard deviation. ***p < 0.001 versus samples lacking BMP-1 in a two-tailed student's t-test.
964 screened
499 patients 
randomized
465 did not meet 
inclusion criteria or 
met exclusion criteria
168 assigned to 
receive placebo
331 assigned to 
receive RVX-208
166 included in mITT analysis
168 included in safety analysis
331 included in primary mITT analysis
331 included in safety analysis
Total safety population = 499 patients
Total mITT population = 497 patients
Fig. 3. Flow chart of patients through the SUSTAIN and ASSURE clinical trials.
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RVX-208 treatment.4. Discussion
ApoA-I is the precursor of new HDL particles, and provides thevehicle to promote RCT. Enhancement of ApoA-I production and
formation of efﬂux-competent HDL can oppose plaque progression,
resulting in increased stability and reduced cardiovascular risk. In
addition to RCT, HDL counters atherosclerosis through antioxidant,
anti-inﬂammatory and antithrombotic mechanisms [37]. Some
pharmacological strategies that increase HDL-c have been
Table 1
Combined analysis of the ASSURE and SUSTAIN phase II trials.
Biomarker RVX-208 (n ¼ 331) Placebo (n ¼ 166) Between treatment difference (%:) p value vs placebo
Baseline Change from baseline (%:) Baseline Change from baseline (%:)
HDL-cholesterol (mg/dL) 39.0 þ3.0 (þ7.69) 38.0 0.0 (0.0) þ3.0 (7.69) 0.0003
ApoA-I (mg/dL) 119.2 þ12.3 (þ10.3) 118.1 þ4.8 (þ3.8) þ7.5 (6.5) 0.005
Large HDL particles (mmol/L) 2.4 þ0.8 (þ30.7) 2.1 þ0.1 (þ4.11) þ0.7 (26.6) 0.03
HDL particle size (nm) 8.7 þ0.1 (þ1.16) 8.7 0.0 (0.0) þ0.1 (1.16) 0.049
Total HDL particles (mmol/L) 27.2 þ1.9 (þ6.51) 26.9 þ0.1 (þ0.40) þ1.8 (6.11) 0.07
LDL-cholesterol (mg/dL) 2.4 0.2 (10.8) 2.3 0.2 (8.05) 0.0 (2.75) NS
Glucose (mmol/L) 5.8 þ0.1 (þ2.08) 5.7 þ0.2 (þ3.57) þ0.1 (þ1.49) NS
hsCRP (mg/L) 2.3 0.36 (28.4) 2.5 0.33 (22.4) 0.03 (6.03) NS
Table 2
Incidence of MACE in the ASSURE and SUSTAIN phase II trials.
Cardiovascular events RVX-208 (n ¼ 331) Placebo (n ¼ 168)
MACE n (%) 18 (5.4) 17 (10.1)
Death n (%) 1 (0.3) 3 (1.8)
Myocardial infarction n (%) 4 (1.2) 0 (0.0)
Coronary revascularization n (%) 9 (2.7) 7 (4.2)
Hospitalization for unstable angina or heart failure n (%) 4 (1.2) 7 (4.2)
Table 3
Pathways that can impact MACE were identiﬁed by microarrays from cryopreserved primary human hepatocytes treated with 30mM RVX-
208 for 48 h. The normalized enrichment score (NES) and the p-value are indicated.
Pathway NES p value
REACTOME_COMPLEMENT_CASCADE 2.30 <0.001
REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE 1.98 <0.001
REACTOME_CHOLESTEROL_BIOSYNTHESIS 1.88 <0.001
INGENUITY_ACUTE_PHASE_RESPONSE_SIGNALING 1.84 <0.001
REACTOME_DIABETES_PATHWAYS 1.67 <0.001
REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS 1.65 0.01
D. Gilham et al. / Atherosclerosis 247 (2016) 48e57 53evaluated in pre-clinical and clinical studies. Current investigation
of RVX-208 through analysis of clinical trials and in vitro studies
show that this novel BETi affects mechanisms that enhances pro-
duction of the ApoA-I protein and HDL particles which are efﬂux-
competent. In addition, microarray-based gene expression ana-
lyses of human primary liver cells and whole blood identify addi-
tional pathways regulated by RVX-208 that contribute to CVD risk.
Studies from laboratories including our own have shown that
BETi with various chemical scaffolds induce ApoA-I gene tran-
scription in hepatocarcinoma cell lines [15,16,20e22]. This report
conﬁrms that BETi induces ApoA-I gene expression in multiple
primary human and primate hepatocyte systems (Figs. 1e2).
Moreover, RVX-208 induces production of new ApoA-I protein that
is detected with an anti-proApoA-I antibody in primary hepatocyte
culture and in patients' serum from the SUSTAIN trial (Fig. 2).
Mature ApoA-I, HDL-c, and HDL particle numbers are also signiﬁ-
cantly elevated in patients receiving RVX-208 in the SUSTAIN/
ASSURE trials (Table 1). We have previously demonstrated
increased efﬂux potential in serum from human trials [15]. In
addition, RVX-208 enhanced cholesterol efﬂux three-fold from J774
macrophages to lipid poor recombinant ApoA-I (data not shown).
Together, these ﬁndings suggest that RVX-208 promotes choles-
terol efﬂux through increased production of ApoA-I by hepatocytes
and maturation into HDL particles, as well as increased efﬂux po-
tential of macrophages.
The data collected in the recently completed phase 2b trials
SUSTAIN and ASSURE provided an opportunity to look at potential
impact of RVX-208 on cardiovascular events. While SUSTAIN did
not pre-specify MACE as an endpoint, in ASSURE, in addition to theprimary endpoint of arterial plaque regression (p ¼ 0.08), MACE
was an exploratory endpoint that showed trending towards a
reduction in patients receiving RVX-208 (data not shown). To
expand on this observation, we performed a post-hoc analysis of
the combined MACE data from the two trials. Treatment with RVX-
208 was associated with lower incidence of MACE (Table 2), but the
magnitude was greater than predicted by changes in ApoA-I/HDL
(Table 2) [38], and thus prompted microarray-based gene expres-
sion analysis to identify properties of RVX-208 beyond lipid and
lipoprotein proﬁle.
Microarray analysis of primary human hepatocytes revealed a
signiﬁcant RVX-208 mediated repression of cholesterol and fatty
acid synthesis, glucose processing and acute phase response (APR)
pathways (Table 3 and Fig. 4). The contribution of cholesterol and
fatty acyl-CoA biosynthesis as well as diabetes pathways on pro-
gression of atherosclerosis is well established. Plasma triglycerides,
LDL-c and diabetes are independent risk factors for CVD [39,40].
However, biologically signiﬁcant changes in LDL-c, triglycerides or
fasting glucose were not observed in the ASSURE/SUSTAIN trials
(Table 1). Components of the APR are pro-inﬂammatory, pro-
atherogenic and markers of CVD risk [41]. Chronic inﬂammation
leads to formation of dysfunctional and pro-inﬂammatory HDL
particles that no longer promote cholesterol efﬂux or prevent LDL
oxidation (reviewed in [42,43]). RVX-208 downregulates expres-
sion of 14 genes that encode APR proteins associated with HDL.
Three of these proteins are also reduced in patients' plasma,
including ceruloplasmin, amyloid P component and complement
C3 (Table 5). Thus, downregulation of APR by RVX-208 may reduce
formation of pro-inﬂammatory HDL and counter the
Fig. 4. Microarray analysis of RVX-208-induced gene expression changes in primary human hepatocytes. Cryopreserved human hepatocytes were treated with 30mM RVX-208 for
48 h. Heatmaps represent log2 fold changes in gene expression in pathways known to impact MACE.
Fig. 5. Microarray analysis of RVX-208-induced gene expression changes in human whole blood. Samples were treated ex-vivo with 20mM RVX-208 for 3 or 24 h. Heatmaps
represent log2-fold changes in expression of genes with known pro- and anti-atherosclerotic functions.
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Table 4
Top pathways downregulated by 20mM RVX-208 identiﬁed in microarrays from
humanwhole blood treated ex vivo for 3 h or 24 h. The normalized enrichment score
(NES) and the p-value are indicated.
Pathway NES p value
REACTOME_COLLAGEN_FORMATION 2.04 <0.001
PID_AVB3_INTEGRIN_PATHWAY 1.97 <0.001
REACTOME_BETA_DEFENSINS 1.78 0.002
REACTOME_DEFENSINS 1.77 0.004
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 1.73 <0.001
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 1.71 0.005
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS 1.66 <0.001
BIOCARTA_DC_PATHWAY 1.65 0.005
PID_INTEGRIN_A9B1_PATHWAY 1.63 0.02
BIOCARTA_TH1TH2_PATHWAY 1.57 0.02
Table 5
RVX-208 reduces circulating levels of cytokines and APR proteins in clinical samples. Multi-Analyte Proﬁling was performed with plasma samples from the ASSURE trial
(N ¼ number of samples) collected at baseline and after the ﬁnal dose of RVX-208.
Multi-analyte proﬁling of plasma samples from clinical trails.
Analyte/Gene symbol N Percent change from baseline p-value vs baseline
Pulmonary And Activation-Regulated (CCL18) 20 22.2 0.01
Serum Amyloid P-Component (APCS) 20 15.0 0.001
Interleukin-18 (IL18) 20 10.3 0.02
Complement C3 (APR and Inﬂammation) 20 9.28 0.002
Ceruloplasmin (CP) (APR) 17 7.35 0.02
Intercellular Adhesion Molecule 1 (ICAM1) 10 6.87 0.01
Interleukin-12 Subunit p40 (IL12B) 19 5.65 0.04
D. Gilham et al. / Atherosclerosis 247 (2016) 48e57 55downregulation of HDL associated with activation of the innate
immune system (reviewed in [43]), resulting in improved HDL
proﬁle as observed in the ASSURE/SUSTAIN trials.
RVX-208 had profound effects on the complement and ﬁbrin
clotting pathways (Table 3 and Fig. 4). Overactivation of the com-
plement pathway has been implicated in plaque development and
destabilization [44,45]. Complement activation also inﬂuences
thrombosis through activation of platelets, promotion of ﬁbrin
formation, and impairment of ﬁbrinolysis. Fibrin clotting is
fundamental in the formation of thrombi and emboli. Fibrin and
ﬁbrinogen degradation products have been associated with CVD
development and severity [46,47], as well as cardiac events and
death [48,49]. Bleeding disorders were not found in clinical trials
with RVX-208, however, downregulation of the ﬁbrin clotting
pathwaymay avoid cardiac events similar to other pharmacological
agents that target coagulation [50].
BETi have well established anti-inﬂammatory properties
[20,22,51]. JQ1 was demonstrated to downregulate inﬂammatory
signaling in vascular endothelial cells and to decrease leukocyte
chemoattraction to endothelium in ApoE/ mice, potentially
leading to reduced atherosclerosis [51]. RVX-208 was shown to
lower inﬂammatory markers in human vascular and monocytic cell
lines and to reduce circulating cytokines in ApoE/ mice [52].
Microarray data summarized here identify pro-inﬂammatory and
pro-atherosclerotic genes that are downregulated by RVX-208 in
primary human hepatocytes and whole blood (Figs. 4 and 5). Many
of the targets repressed by RVX-208 are expressed at high levels in
patients with atherosclerosis and CVD, and the corresponding
protein levels are predictive of the disease. For example, plasma
levels of secreted phosphoprotein 1 (SPP1) predict MACE in pa-
tients with coronary artery disease [53e55] or type 1 diabetes [56],
while CCL23 and Toll-like receptor 2 are independent risk factors
for atherogenesis [57,58]. It was previously shown that RVX-208
downregulates aortic CCL2 in mice and in human aortic endothe-
lial cells [52]. Downregulation of CCL2 and its receptor CCR2 in
human blood conﬁrms that RVX-208 can interfere with this pro-inﬂammatory signaling axis. This is of importance as CCR2 is the
target of developing anti-atherosclerotic therapies [59]. Further-
more, FN1, CCL2, CCL18 and SPP1 were upregulated in blood taken
from sites of occlusion during acute myocardial infarction, indi-
cating they either play a direct role in the acute event or they
constitute a tissue response to the occlusion [60]. Importantly,
these four are amongst the top 10 downregulated genes in RVX-
208-treated whole blood, suggesting that treatment with RVX-208
may disrupt pathogenic pathways underlying CVD and/or an acute
event.
Based on ﬁndings in microarrays, we analyzed plasma samples
from our clinical trials and found decreased level of circulating
cytokines vs. baseline in patients receiving RVX-208. SpeciﬁcallyCCL18 (PARC) and IL-18 were reduced by 22% and 10%, respec-
tively (Table 5). These ﬁndings matched microarray data from RVX-
208 treated whole blood showing a 7-fold repression of CCL18 and
from primary hepatocytes, where a 3-fold repression of IL-18 was
observed. Both cytokines play a role in CVD and are associated with
MACE [54,61]. Furthermore, IL-18 neutralizing antibodies are being
tested for clinical beneﬁt [62], thus highlighting the potential of
RVX-208 in reducing CVD.
Elevation of serum inﬂammatory markers is consistently asso-
ciated with risk of MACE. In the ASSURE trial, MACE rate was
reduced particularly in RVX-208-treated patients with elevated
levels of the inﬂammatory marker CRP (2 mg/L) [63]. Thus, RVX-
208 may have more favorable effects in the context of systemic
inﬂammation, which is consistent with effects on inﬂammatory
gene expression in liver and whole blood.
In summary, RVX-208 targets multiple processes that underlie
CVD, including reverse cholesterol transport, atherogenesis,
thrombosis and vascular inﬂammation. Transcriptional changes
in any of these pathways, independently or cumulatively, may
impact CVD and lower incidence of MACE observed in the
ASSURE and SUSTAIN trials. These effects of RVX-208 are
consistent with an epigenetic mechanism of action of BETi that
modulate transcription of genes and pathways which can drive
disease [51]. Downregulation of multiple pathogenic processes
by inhibiting a single target is an attractive property of RVX-208
that can be used to treat a complex multifactorial disease such as
CVD.
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